title: Augmentation of venlafaxine with bupropion: risks associated with a triple monoamine reuptake inhibition approach to partially responsive depression.
authors.affiliation: Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India. candrade@psychiatrist.com
authors.forename: Chittaranjan
authors.initials: C
authors.lastname: Andrade
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016642:Bupropion / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003511:Cyclohexanols / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004347:Drug Interactions; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D017211:Treatment Failure; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D016642:Bupropion; D000069470:Venlafaxine Hydrochloride